• Founder’s Vision
  • ANKTIVA
  • BCG
  • Our Science
  • Careers
  • Contact
ImmunityBio
  • Patients & Caregivers
    • ANKTIVA®
    • Clinical Trials
    • Patients
    • Therapeutic Areas
      • Bladder Cancer
      • Glioblastoma
      • HIV
      • Human Papillomavirus
      • Lymphopenia
      • Lynch Syndrome
      • Non-Hodgkin Lymphoma
      • Non-Small Cell Lung Cancer
      • Ovarian Cancer
  • Healthcare Providers
    • ANKTIVA®
    • Clinical Trials
    • Trial Investigators
    • Expanded Access
  • Researchers
    • Platforms & Modalities
    • Trial Investigators
    • Cell Licensing
    • Publications
  • Our Company
    • About
    • Pipeline
    • Contact
    • Compliance & Transparency
  • News and Events
  • Investors
Select Page
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge

Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge

Sep 17, 2021 | COVID-19, SARS-CoV-2

A deep learning-based iterative digital pathology annotation tool

A deep learning-based iterative digital pathology annotation tool

Aug 24, 2021 | Non-Small Cell Lung Cancer, Triple Negative Breast Cancer

Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice

Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice

Jul 23, 2021 | COVID-19

A deep learning-based iterative digital pathology annotation tool

Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant

May 6, 2021 | COVID-19

A deep learning-based iterative digital pathology annotation tool

Single Prime hAd5 Spike (S) + Nucleocapsid (N) Dual Antigen Vaccination of Healthy Volunteers Induces a Ten-Fold Increase in Mean S- and N- T-Cell Responses Equivalent to T-Cell Responses from Patients Previously Infected with SARS-CoV-2

May 6, 2021 | COVID-19

« Older Entries

Recent Posts

  • H.C. Wainwright 27th Annual Global Investment Conference
  • ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
  • Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
  • World Conference on Lung Cancer
  • ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
 

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  X
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2025 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap